Chemours (CC) Projected to Post Earnings on Thursday

Chemours (NYSE:CC) is anticipated to announce its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Chemours to post earnings of $0.01 per share and revenue of $1.3284 billion for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 20, 2026 at 8:00 AM ET.

Chemours Price Performance

CC stock opened at $21.01 on Thursday. The company’s 50-day moving average is $14.21 and its 200-day moving average is $14.09. The stock has a market capitalization of $3.15 billion, a PE ratio of -9.47 and a beta of 1.63. The company has a debt-to-equity ratio of 13.66, a current ratio of 1.71 and a quick ratio of 0.88. Chemours has a 1 year low of $9.13 and a 1 year high of $21.09.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CC. Royal Bank Of Canada reiterated an “outperform” rating and set a $18.00 price objective on shares of Chemours in a report on Friday, January 16th. JPMorgan Chase & Co. dropped their price objective on shares of Chemours from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, December 3rd. Truist Financial upped their target price on shares of Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, January 21st. UBS Group dropped their target price on shares of Chemours from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, November 11th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $20.00 price target on shares of Chemours in a research note on Monday, January 19th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $16.67.

Institutional Trading of Chemours

Several institutional investors have recently added to or reduced their stakes in CC. State Street Corp grew its holdings in Chemours by 22.7% during the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after purchasing an additional 1,131,682 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Chemours by 13.8% in the third quarter. Ameriprise Financial Inc. now owns 4,796,153 shares of the specialty chemicals company’s stock valued at $75,971,000 after purchasing an additional 580,089 shares in the last quarter. UBS Group AG increased its holdings in shares of Chemours by 0.3% in the 3rd quarter. UBS Group AG now owns 4,754,492 shares of the specialty chemicals company’s stock worth $75,311,000 after buying an additional 14,865 shares during the last quarter. Cooper Creek Partners Management LLC purchased a new stake in Chemours during the third quarter valued at approximately $63,103,000. Finally, Goldman Sachs Group Inc. boosted its stake in Chemours by 36.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,701,294 shares of the specialty chemicals company’s stock worth $43,638,000 after buying an additional 996,012 shares during the period. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.